Cellectis Reports Financial Results For First Quarter 2024

. Cellectis announced completion of the additional equity investment of $140M by AstraZeneca . Cash position of $143 million as of March 31

Related Keywords

France ,United States ,United Kingdom ,Marc Dunoyer ,Bing Wang ,Nasdaq ,International Accounting Standards Board ,Cellectis The Company Euronext Growth ,Allogeneic Car Development Programs ,European Union ,Research Plan ,Astrazeneca ,International Financial Reporting Standards ,Euronext Growth ,Chief Executive Officer ,Development Programs ,Investment Agreements ,Arthur Stril ,Interim Chief Financial Officer ,Tyrell Rivers ,Subsequent Investment Agreement ,Net Income ,Regarding Use ,North Carolina ,